ArticleBMC medical imaging2026
Utilizing imaging features of preoperative gadoxetic acid-enhanced MRI for predicting lymphovascular invasion in colorectal cancer liver metastases and exploring its impact on survival.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo construct an imaging model based on preoperative gadoxetic acid- enhanced MRI for predicting lymphovascular invasion (LVI) in colorectal cancer liver metastases (CRLM) and explore its impact on survival.
methodA total of 91 patients with CRLM were retrospectively enrolled in this study. The liver lesions were categorized into two groups, with LVI and without LVI by pathological examination. The long diameter, vascular penetration sign, peritumoral hepatobiliary phase (HBP) hypointensity and other qualitative signs were evaluated. The mean value and standard deviation (SD) value of signal intensity (SI) of the liver lesion and the region with 5-mm tumor expansion were recorded. The relative enhancement rate (RER) was calculated on each phase. Univariate and multivariate logistic regression were used to construct the imaging model (LVI
resultsThe vascular penetration sign (odds ratio [OR] = 30.052, p<0.001) and SD of tumor on HBP (SD
conclusionThe imaging model based on vascular penetration sign and SD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.